Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
paracetamol + meloxicam
- Development stage
- Unknown
- Lead developer
- Aristo Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral, Intramuscular, Intravenous
01
Overview
**Paracetamol + meloxicam** is an oral fixed-dose analgesic combination containing paracetamol, also called acetaminophen, and meloxicam. Meloxicam is an oxicam nonsteroidal anti-inflammatory drug that inhibits cyclooxygenase-mediated prostaglandin synthesis, while paracetamol provides analgesic and antipyretic activity through a mechanism thought to act primarily in the central nervous system. Marketed tablet presentations include 7.5 mg meloxicam plus 325 mg paracetamol and are used for pain and inflammation associated with musculoskeletal conditions, including osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis. ([1mg.com](https://www.1mg.com/drugs/melodol-tablet-302959))
- Brand names
- MelodolPaincon Forte
- Other names
- acetaminophen + meloxicammeloxicam + acetaminophenmeloxicam + paracetamolparacetamol + meloxicam
02
Targets
COX-3 (Mitochondrially encoded cytochrome c oxidase subunit 3)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)PGHS-1 (Prostaglandin G/H Synthase 1)
Beyond the preview
Go deeper on paracetamol + meloxicam.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on paracetamol + meloxicam.